Skip to main content

Genotyping Assay Market Worth USD 31.9 Billion : Decreasing Prices Of DNA Sequencing

 Major Growth Boosters:

The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years. The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.

What This Report Will Provide?

Genotyping platforms have several potential application areas such as pharmacogenomics, diagnostic research, personalized medicine, and forensics. Furthermore, this technology is also apt for a range of veterinary needs, food safety and quality, and environmental testing in remote areas and industrial settings. At present, human diagnostics and pharmacogenomics offer significant marker potential as these segments require rapid genotyping analysis on a large scale due to the need for better treatment options and high disease prevalence.

Expected Revenue Growth:

MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (OTC:CAGR) of 22.0% during the forecast period.



 Recent Developments

  • In May 2018, Agilent technologies opened a new logistics center in Texas to increase its capacity for house inventory and to fulfill the growing demand for NGS products from its genomics group.
  • In March 2018, Danaher Corporation acquired Integrated DNA Technologies Inc. (US). This acquisition strengthened Danaher’s Life Sciences platform. IDT will operate as a standalone operating company and brand within Danaher Corporation.
  • In January 2018, Thermo Fisher Scientific signed a partnership with Illumina (US) that enabled Illumina to sell the Ion AmpliSeq technology to researchers who conduct scientific studies using Illumina’s next-generation sequencing (NGS) platforms.
  • In January 2018, Illumina launched the iSeq 100 Sequencing System.
  • In January 2018, Thermo Fisher Scientific launched the Ion GeneStudio S5 Series Instrument.

Key Questions Addressed in The Report:

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the genotyping market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading players operating in this market?
  • What are the opportunities for new market entrants?

Request Sample Report:   ttps://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595 

Technological Advancements and Decreasing Prices of DNA Sequencing

Technical advancements have allowed for miniaturization, automation, and reduced overall costs, as well as operational flexibility and the incorporation of multi-parameter testing. All of these have greatly helped increase the applications and convenience of DNA sequencing, allowing physicians to focus on high-level decision-making such as identifying and prioritizing drug targets through various genotyping studies. This has directly boosted the uptake of PCR, sequencing, capillary electrophoresis, and microarray technologies in fields such as drug discovery and clinical research.

Regional Growth Analysis:

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Download PDF Brochure:     https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595 

Labels:

Comments

Post a Comment

Popular posts from this blog

Healthcare BPO Market To Reach $312.43 Billion By 2022 : Increasing Consolidation In The Healthcare Industry

  What This Report Will Provide? In the current market scenario, there is a growing demand for healthcare BPO services. The objective of this report is to define, describe, and forecast the market on the basis of outsourcing services including payer, provider, and pharmaceutical services and region. It provides detailed information regarding the major factors influencing the growth of healthcare outsourcing market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials. Expected Revenue Growth: Healthcare BPO market  is estimated to grow at a CAGR of 10.2% from 2017 to 2022 to reach $312.43 billion by 2022 from $191.68 billion in 2017. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Major Growth Boosters: Patent cliffs, complex clinical trial protocols, and new reporting requirements are forcing pha...
Post a Comment
Read more

Autoinjectors Market | Newest Industry Data, Future Trends and Forecast 2023

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs. The  global autoinjectors market  is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). In terms of Therapy, the global autoinjectors market can be segmented into: Rheumatoid Arthritis Multiple Sclerosis Diabetes Anaphylaxis Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia) By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therap...
Post a Comment
Read more

North American Nuclear Medicine Market To Reach USD 2.7 Billion By 2024 – Expansion In Emerging Economies

  What This Report Will Provide? The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Expected Revenue Growth: [159 Pages Report] The  North American nuclear medicine market  is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. Major Growth Boosters: Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment...
Post a Comment
Read more